Adriamycin-a review.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D008938:Mitosis / Q000187:drug effects; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009447:Neuroblastoma / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D013964:Thyroid Neoplasms / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D004317:Doxorubicin